Emory University School of Medicine
Emory University School of Medicine
Department of Pathology and Laboratory Medicine

Pathology Home section navigation

Department of Pathology and Laboratory Medicine

Selected Peer Reviewed Publications

The research interests of the laboratory span all areas in breast diseases from benign, high risk and precursor lesions to malignant tumors. The current focus of the laboratory is to develop biomarkers to predict breast cancer risk, development, prognosis and tumor response to therapies.

2023

  1. Si Wu, Meng Yue, Jun Zhang, Xiaoxian Li, Zaibo Li, Huina Zhang, Xinran Wang, Xiao Han, Lingjing Cai, Jiuyan Shang, Zhanli Jia, Xiaoxiao Wang, Jinze Li, Yueping Liu. The role of artificial intelligence in accurate interpretation of HER2 IHC 0 and 1+ in breast cancers.  Modern Pathology. 2023 Jan 10;36(3):100054. doi: 10.1016/j.modpat.2022.100054. Online ahead of print.PMID: 36788100

  2. Thaer Khoury, Marilin Rosa, Anupma Nayak, Rouzan G. Karabakhtsian, Oluwole Fadare, Zaibo Li, Bradley M Turner, Yisheng V Fang, Asangi Kumarapeli, Xiaoxian (Bill) Li, Numbereye Numbere, Tatiana M Villatoro, Ji-Gang Wang, Saed Sadeghi, Kristopher Attwood, Anthony George, and Rohit Bhargava. Clinicopathological Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study. Mod Pathol. 2023 Feb;36(2):100006. doi: 10.1016/j.modpat.2022.100006. Epub 2023 Jan 9.PMID: 36853781

  3. Wu S, Yue M, Zhang J, Xiaoxian Li, Li Z, Zhang H, Wang X, Han X, Cai L, Shang J, Jia Z, Wang X, Li J, Liu Y.  The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer. Mod Pathol. 2023 Jan 10;36(3):100054. doi: 10.1016/j.modpat.2022.100054. Online ahead of print. PMID: 36788100

  4. Garlapati C, Joshi S, Bhattarai S, Krishnamurthy J, Turaga RC, Nguyen T, Xiaoxian Li, Aneja R. PLK1 and AURKB phosphorylate survivin differentially to affect proliferation in racially distinct triple-negative breast cancer. Cell Death Dis. 2023 Jan 10;14(1):12. doi: 10.1038/s41419-022-05539-5. PMID: 36627281

  5. Lewis G, Fong N, Gjeorgjievski S G, Xiaoxian Li, Li Z, Wei S, Sturgis C D, Wang C, Komforti M, Zhang H, Downs-Kelly E, Cui X, McIntire P, Hoda R, J JordiRowe, Sciallis A & Zhang G. Low-grade adenosquamous carcinoma of the breast: a clinical, morphological and immunohistochemical analysis of 25 patients. Histopathology. 2023 Apr 17. doi: 10.1111/his.14917. Online ahead of print. PMID: 37067767

  6. Cheng RY, Ridnour LA, Wink AL, Gonzalez AL, Femino EL, Rittscher H, Somasundarum V, Heinz WF, Coutinho L, Cristina Rangel M, Edmondson EF, Butcher D, Kinders RJ, Xiaoxian Li, Wong STC, McVicar DW, Anderson SK, Pore M, Hewitt SM, Billiar TR, Glynn S, Chang JC, Lockett SJ, Ambs S, Wink DA. Interferon-gamma is Quintessential for NOS2 and COX2 Expression in ER - Breast Tumors that Lead to Poor Outcome. bioRxiv. 2023 Apr 6:2023.04.06.535916. doi: 10.1101/2023.04.06.535916. Preprint. PMID: 37066331

  7. Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Xiaoxian Li, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group. J Pathol. 2023 Aug 23. doi: 10.1002/path.6155. Epub ahead of print. PMID: 37608772.

  8. Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Xiaoxian Li, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Salomon AV, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Bartlett JMS, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E, Akturk G, Bouchmaa N. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. J Pathol. 2023 Aug 23. doi: 10.1002/path.6165. Epub ahead of print. PMID: 37608771.

  9. Wang Q, Bradley K, Zhang M, Li S, Xiaoxian Li. Rosai-Dorfman Disease of the Breast: A Clinicoradiologic and Pathologic Study. Hum Pathol. 2023 Sep 4:S0046-8177(23)00184-3. doi: 10.1016/j.humpath.2023.08.009. Epub ahead of print. PMID: 37673345.

  10. Turashvili G, Gjeorgjievski SG, Wang Q, Ewaz A, Ai D, Xiaoxian Li, Badve SS. Intraoperative assessment of axillary sentinel lymph nodes by telepathology. Breast Cancer Res Treat. 2023 Sep 9. doi: 10.1007/s10549-023-07101-z. Epub ahead of print. PMID: 37688667.

  11. Turashvili G, Ding Q, Liu Y, Peng L, Mrkonjic M, Mejbel H, Wang Y, Zhang H, Zhang G, Wang J, Wei S, Xiaoxian Li. Comprehensive Clinical-Pathologic Assessment of Malignant Phyllodes Tumors: Proposing Refined Diagnostic Criteria. Am J Surg Pathol. 2023 Sep 11. doi: 10.1097/PAS.0000000000002109. Epub ahead of print. PMID: 37694517.

  12. Turashvili G, Gao Y, Ai DA, Ewaz AM, Gjeorgjievski SG, Wang Q, Nguyen TTA, Zhang C, Xiaoxian Li. Low interobserver agreement among subspecialised breast pathologists in evaluating HER2-low breast cancer. J Clin Pathol. 2023 Sep 15:jcp-2023-209055. doi: 10.1136/jcp-2023-209055. Epub ahead of print. PMID: 37714693.

  13. Hart S, Garcia V, Dudgeon SN, Hanna MG, Xiaoxian Li, Blenman KR, Elfer K, Ly A, Salgado R, Saltz J, Gupta R, Hytopoulos E, Larsimont D, Lennerz J, Gallas BD. Initial interactions with the FDA on developing a validation dataset as a medical device development tool. J Pathol. 2023 Oct 4. doi: 10.1002/path.6208. Epub ahead of print. PMID: 37794720.

  14. Xiaoxian Li, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. Correlation of HER2 Protein Level with mRNA Level Quantified by RNAscope in Breast Cancer. Mod Pathol. 2023 Dec 20:100408. doi: 10.1016/j.modpat.2023.100408. Epub ahead of print. PMID: 38135153.

  15. Ai D, Turashvili G, Gjeorgjievski SG, Wang Q, Ewaz AM, Gao Y, Nguyen T, Zhang C, Xiaoxian Li. Subspecialized breast pathologists have suboptimal interobserver agreement in Ki-67 evaluation using 20% as the cutoff. Breast Cancer Res Treat. 2023 Dec 29. doi: 10.1007/s10549-023-07197-3. Epub ahead of print. PMID: 38157098.

  16. Ridnour LA, Heinz WF, Cheng RY, Wink AL, Kedei N, Pore M, Imtiaz F, Femino EL, Gonzalez AL, Coutinho L, Butcher D, Edmondson EF, Rangel MC, Kinders RJ, Lipkowitz S, Wong ST, Anderson SK, McVicar DW, Xiaoxian Li, Glynn SA, Billiar TR, Chang JC, Hewitt SM, Ambs S, Lockett SJ, Wink DA. NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER-Breast Cancer. bioRxiv [Preprint]. 2023 Dec 23:2023.12.21.572859. doi: 10.1101/2023.12.21.572859. PMID: 38187532; PMCID: PMC10769386.

  17. Ridnour LA, Cheng RYS, Heinz WF, Pore M, Gonzalez AL, Femino EL, Moffat R, Wink AL, Imtiaz F, Coutinho L, Butcher D, Edmondson EF, Rangel MC, Wong STC, Lipkowitz S, Glynn S, Vitek MP, McVicar DW, Xiaoxian Li, Anderson SK, Paolocci N, Hewitt SM, Ambs S, Billiar TR, Chang JC, Lockett SJ, Wink DA. Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients. bioRxiv [Preprint]. 2023 Dec 23:2023.12.21.572867. doi: 10.1101/2023.12.21.572867. PMID: 38187660; PMCID: PMC10769421.

  18. Turashvili G, Xiaoxian Li. Hot Topics in Breast Pathology. Arch Pathol Lab Med. 2023 Sep 1;147(9):1001-1002. doi: 10.5858/arpa.2023-0194-ED. PMID: 37651392.

  19. Turashvili G, Xiaoxian Li. Inflammatory Lesions of the Breast. Arch Pathol Lab Med. 2023 May 15. doi: 10.5858/arpa.2022-0477-RA. Epub ahead of print. PMID: 37196345.

2022

  1. Thi Truc Anh Nguyen, Lauren M. Postlewait, Chao Zhang, Jane Meisel, Ruth O’Regan, Sunil Badve, Kevin Kalinsky, and Xiaoxian Li. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative and lymph node negative breast cancer. Breast Cancer Res Treat. 2022 Jan 27. doi: 10.1007/s10549-022-06530-6. Online ahead of print. PMID: 35084624.
  2. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Xiaoxian Li, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022 May 4:clincanres.CCR-21-3100-A.2021. doi: 10.1158/1078-0432.CCR-21-3100. Online ahead of print. PMID: 35507014
  3. Victor Garcia, Katherine Elfer, Dieter J.E. Peeters, Anna Ehinger, Bruce Werness, Amy Ly, Xiaoxian Li, Matthew G. Hanna, Kim R.M. Blenman, Roberto Salgado, Brandon D. Gallas. Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer. Cancers (Basel). 2022 May 17;14(10):2467. doi: 10.3390/cancers14102467. PMID: 35626070
  4. Joseph Butner, Prashant Dogra, Caroline Chung, Javier Ruiz Ramírez, Sara Nizzero, Marija Plodinec, Xiaoxian Li, Ping-Ying Pan, Shu-hsia Chen, Vittorio Cristini, Bulent Ozpolat, George Calin, and Zhihui Wang. Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. Cell Death & Disease. 2022 May 21;13(5):485. doi: 10.1038/s41419-022-04939-x. PMID: 35597788
  5. Thaer Khoury, Marilin Rosa, Anupma Nayak, Rouzan G. Karabakhtsian, Oluwole Fadare, Zaibo Li, Bradley M Turner, Yisheng V Fang, Asangi Kumarapeli, Xiaoxian (Bill) Li, Numbereye Numbere, Tatiana M Villatoro, Ji-Gang Wang, Saed Sadeghi, Kristopher Attwood, Anthony George, and Rohit Bhargava. Clinicopathological Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study. Modern Pathology. In press
  6. Hongxiao Li, Jigang Wang, Zaibo Li, Melad Dababneh, Fusheng Wang, Peng Zhao, Geoffrey H Smith, George Teodoro, Meijie Li, Jun Kong and Xiaoxian Li. Deep learning-based pathology image analysis enhances Magee feature correlation with Oncotype DX Breast Recurrence Score. Front Med (Lausanne). 2022 Jun 14;9:886763. doi: 10.3389/fmed.2022.886763. eCollection 2022.PMID: 35775006
  7. Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt, Tejal Patel, Bin Teh, Andrew Farach, Carlo Guerrero, Sunil Mathur, Mark Sultenfuss, Nakul Gupta, Mary R. Schwartz, Susan Haley, Sindhu Nair, Xiaoxian Li, Thi Truc Anh Nguyen, Joseph D. Butner, Joe Ensor, Jamie Mejia, Zhouyong Mei, E. Brian Butler, Shu-hsia Chen, Eric H. Bernicker, Jenny C. Chang. Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer. Clin Cancer Res. In press.
  8. Katherine Elfer, Sarah Dudgeon, Victor Garcia, Kim Blenman, Evangelos Hytopoulos, Si Wen, Xiaoxian Li, Amy Ly, Bruce Werness, Manasi S. Sheth, Mohamed Amgad, Rajarsi Gupta, Joel Saltz, Matthew G. Hanna, Anna Ehinger, Dieter Peeters, Roberto Salgado, Brandon D. Gallas. Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms. Journal of Medical Imaging. In press.

2021

  1. Koca E, Niravath PA, Ensor J, Patel TA, Xiaoxian Li, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang JCN. ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2021 Apr 15. doi: 10.1007/s10549-021-06214-7. Online ahead of print. PMID: 33860388
  2. Kenong Su, Ronglai Shen, Shi-Yong Sun, Carlos S. Moreno, Xiaoxian Li, and Zhaohui Qin. Pan-cancer analysis of pathway-based gene expression pattern at the individual level reveals biomarkers of clinical prognosis. Cell Reports. Cell Rep Methods. 2021 Aug 23;1(4):100050. doi: 10.1016/j.crmeth.2021.100050. Epub 2021 Jul 23. PMID: 34671755
  3. Huang L, Bommireddy R, Munoz LE, Guin RN, Wei C, Ruggieri A, Menon AP, Xiaoxian Li, Shanmugam M, Owonikoko TK, Ramalingam SS, Selvaraj P. Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor. Plos One. 2021 Aug 19;16(8):e0254125. doi: 10.1371/journal.pone.0254125. eCollection 2021. PMID: 34411144
  4. Tiansheng Shen, Lai Wei, Xiaoxian Li, Anil Parwani and Zaibo Li. Prognostic value of androgen receptor expression and molecular alterations in metastatic triple negative or low hormone receptor breast carcinomas. Hum Pathol. 2021 Jul 24;116:73-81. doi: 10.1016/j.humpath.2021.07.008. Online ahead of print. PMID: 34310983
  5. Alexandra Hart, Udayan Betarbet, Xiaoxian Li, Grant Carlson, Albert Losken. The incidence of occult malignant and high-risk pathology in breast reduction specimens. Plastic and Reconstructive Surgery. 2021 Oct 1;148(4):534e-539e. doi: 10.1097/PRS.0000000000008336. PMID: 34550926
  6. El Bairi K, Haynes HR, Blackley E, et al; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1. PMID: 34853355

2020

  1. Thaer Khoury, Yisheng Fang, Rouzan Karabakhtsian, Mohamed Mokhtar Desouki, Anupma Nayak, Mathew Hanna, Souzan Sanati, Xuan Peng, Li Yan, Xiaoxian Li, Oluwole Fadare, Christine Ambrosone, Nashwan Jabbour, Carmelo Gaudioso. The Clinical Significance of Metastatic Breast Carcinoma to Intra-Mammary Lymph Node. Breast. 2020 Feb;26(2):197-205. doi: 10.1111/tbj.13636. Epub 2019 Oct 6. PMID: 31588665.
  2. Angela Ogden, Shristi Bhattarai, Bikram Sahoo, Nigel Mongan, Mansour Alsaleem, Andrew Green, Mohammed Aleskandarany, Ian O Ellis, Sonal Pattni, Xiaoxian Li, Carlos Moreno, Uma Krishnamurti, Emiel Janssen, Kristin Jonsdottir, Emad Rakha, Padmashree Rida, and Ritu Aneja. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Sci Rep. 2020 Feb 20;10(1):3009. doi: 10.1038/s41598-020-59514-1. PMID: 32080212. 
  3. Xiaoxian Li, Michael Aho, Mary S. Newell, Kelly Clifford, Jay G. Patel, Stephanie Jou, Michael A. Cohen. Benign Papillomas diagnosed on image-guided core biopsy do not require obligatory excision. Clinical Imaging. 2020 Mar;60(1):67-74. doi: 10.1016/j.clinimag.2019.10.009. Epub 2019 Dec 3. PMID: 31864203.
  4. Aidan C. Li, Jing Zhao, Chao Zhao, Zhongliang Ma, Ramon Hartage, Yunxiang Zhang, Xiaoxian (Bill) Li* and Anil V. Parwani*. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma. Breast Cancer Res Treat. 2020 Apr;180(2):321-329. doi: 10.1007/s10549-020-05546-0. Epub 2020 Jan 30. PMID: 32002765. Co-corresponding author.
  5. Rohit Bhargava, Nicole Esposito, Siobhan O'Connor, Zaibo Li, Bradley Turner, Ioana Moisini, Aditi Ranade, Ronald Harris, Dylan Miller, Xiaoxian (Bill) Li, Harrison Moosavi, Beth Clark, Adam M. Brufsky, and David Dabbs. Magee Equations™ and Response to Neoadjuvant Chemotherapy in ER+/HER2-Negative Breast Cancer: A Multi-Institutional Study. Modern Pathology. 2021 Jan;34(1):77-84. doi: 10.1038/s41379-020-0620-2. Epub 2020 Jul 13. PMID: 32661297
  6. Jing Zhao, Uma Krishnamurti, Chao Zhang, Jane Meisel, Zhimin Wei, Aili Suo, Ritu Aneja, Zaibo Li, Xiaoxian Li. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology-Research and Practice. 2020 Aug 10;216(11):153155. doi: 10.1016/j.prp.2020.153155. Online ahead of print.PMID: 32871536
  7. Zhongliang Ma, Cletus Arciero, Toncred Styblo, Haibo Wang, Michael Cohen, Xiaoxian Li. Patients with benign papilloma diagnosed on core biopsies and concordant pathology-radiology findings can be followed: experiences from multi-specialty high risk breast lesion conferences in an academic center. Breast Cancer Res Treat. 2020 Oct;183(3):577-584. doi: 10.1007/s10549-020-05803-2. Epub 2020 Jul 23.PMID: 32705378
  8. Xiaoxian Li, Zhongliang Ma, Toncred M Styblo, Cletus A Arciero, Haibo Wang, Michael A Cohen. Management of high risk breast lesions diagnosed on core biopsies, experiences from prospective high risk breast lesion conferences at an academic institution. Breast Cancer Res Treat. 2021 Feb;185(3):573-581. doi: 10.1007/s10549-020-05977-9. Epub 2020 Oct 17. PMID: 33068196
  9. Jing Zhao, Jane Meisel, Yi Guo, Rita Nahta, Kung Lin Hsieh, Limin Peng, Zhimin Wei, Ruth O’Regan, Xiaoxian Li. Evaluation of PD-L1, tumor infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies. Breast Cancer Res Treat. 2020 Oct;183(3):599-606. doi: 10.1007/s10549-020-05819-8. Epub 2020 Jul 26.PMID: 32715443
  10. Cletus Arciero, Albert H Diehl III, Yuan Liu, Theresa Gillespie, Xiaoxian Li, Preeti Subhedar. Triple Negative Apocrine Carcinoma: A Rare Pathologic Subtype with a Better Prognosis than Other Triple Negative Breast Cancers. J Surg Oncol. 2020 Nov;122(6):1232-1239. doi: 10.1002/jso.26129. Epub 2020 Jul 15.PMID: 32668059.
  11. Yi Guo, Cletus A Arciero, Renjian Jiang, Madhusmita Behera, Limin Peng, Xiaoxian Li. Different breast cancer subtypes show different metastatic patterns, a study from a large public database. Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3587-3593. doi: 10.31557/APJCP.2020.21.12.3587. PMID: 33369456

2019

  1. Elisavet Paplomata, Amelia Zelnak, Cesar Santa-Maria, Yuan Liu, Keerthi Gogineni, Xiaoxian Li, Carlos Moreno, Zhengjia Chen, virginia kaklamani, Ruth O'Regan. Addition of everolimus and trastuzumab to ET in hormone-refractory metastatic breast cancer. Clin Breast Cancer. 2019 Jun;19(3):188-196. doi: 10.1016/j.clbc.2018.12.017. Epub 2019 Jan 3. PMID: 30745109.
  2. Cletus A Arciero, Yi Guo, Renjian Jiang, Madhusmita Behera, Ruth O’Regan, Limin Peng Xiaoxian Li. ER+/HER2+ breast cancer has different metastatic patterns and better survival than ER-/HER2+ breast cancer. Submitted to Clin Breast Cancer. 2019 Aug;19(4):236-245. doi: 10.1016/j.clbc.2019.02.001. Epub 2019 Feb 14. PMID: 30846407.
  3. Shristi Bhattarai 1, Sergey Klimov, Karuna Mittal, Uma Krishnamurti, Xiaoxian Li, et al and Ritu Aneja. Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers. 2019 Jul 17;11(7):995. doi: 10.3390/cancers11070995. PMID: 31319547.
  4. Frank Schneider, Yulan Jin, Kevin Van Smaalen, Evin H Gulbahce, Rachel E Factor, Xiaoxian Li. The FDA approved breast cancer HER2 evaluation kit (HercepTest,Dako) may miss some HER2 positive breast cancers. Submitted to Am J Clin Pathol. 2019 Apr 2;151(5):504-510. doi: 10.1093/ajcp/aqy171. PMID: 30668632.
  5. Tejal A. Patel; Joe E. Ensor; Sarah L. Creamer; Toniva Boone; Angel A. Rodriguez; Poly A. Niravath; Jorge G. Darcourt; Jane L. Meisel; Xiaoxian Li; Jing Zhao; John G. Kuhn; Roberto R. Rosato; Wei Qian; Anna Belcheva; Mary R. Schwartz; Virginia G. Kaklamani; Jenny Chang. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Research. 2019 Sep 2;21(1):100. doi: 10.1186/s13058-019-1186-0. PMID: 31477168.
  6. Jane L. Meisel, Jing Zhao, Aili Suo, Chao Zhang, Zhimin Wei, Zhongliang Ma, Caitlin Taylor, Ritu Aneja, Uma Krishnamurti, Zaibo Li, Rita Nahta, Ruth O’Regan, Xiaoxian Li. Clinicopathologic factors associated with response to neoadjuvant anti-HER2-directed chemotherapy in HER2-positive breast cancer. Clin Breast Cancer. 2020 Feb;20(1):19-24. doi: 10.1016/j.clbc.2019.09.003. Epub 2019 Sep 18. PMID: 31806448.
  7. Thaer Khoury, Yisheng Fang, Rouzan Karabakhtsian, Mohamed Mokhtar Desouki, Anupma Nayak, Mathew Hanna, Souzan Sanati, Xuan Peng, Li Yan, Xiaoxian Li, Oluwole Fadare, Christine Ambrosone, Nashwan Jabbour, Carmelo Gaudioso. The Clinical Significance of Metastatic Breast Carcinoma to Intra-Mammary Lymph Node. Breast. 2020 Feb;26(2):197-205. doi: 10.1111/tbj.13636. Epub 2019 Oct 6. PMID: 31588665.

2018

  1. Neely C, You S, Mendoza PM, Aneja R, Sahin AA, and Xiaoxian Li. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases. Breast. 2018 Nov;24(6):889-893. doi: 10.1111/tbj.13110. Epub 2018 Sep 19. PMID: 30230095.
  2. Meisel J, Zhang C, Neely C, Mendoza P, You S, Han T, Liu Y, Sahin AA, O’Regan R, and Xiaoxian Li. Evaluation of prognosis in hormone receptor positive/HER2 negative and lymph node negative breast cancer with low Oncotype DX recurrence score. Clin Breast Cancer. 2018 Oct;18(5):347-352. doi: 10.1016/j.clbc.2017.12.006. Epub 2017 Dec 14. PMID: 29305309.
  3. Xiaoxian Li, Yiran Zhang, Jane Meisel, Renjian Jiang, Madhusmita Behera , Limin Peng. Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database. Breast Cancer Res Treat. 2018 Sep;171(2):303-313. doi: 10.1007/s10549-018-4832-9. Epub 2018 Jun 15. PMID: 29948405.
  4. Yanjun Hou, Harrison S. Moosavi, Lai Wei, Anil V. Parwani. Xiaoxian Li and Zaibo Li. Magee Equation Recurrence Score Is Associated With to Predict Distal Metastatic Risk in Male Breast Carcinomas: Experience From Two Institutions. Am J Clin Pathol. 2018 Oct 24;150(6):491-498. doi: 10.1093/ajcp/aqy078. PMID: 30084931.
  5. Ashley Schlafstein, Allison Withers, Soumon Rudra, Diana Danelia, Jeffrey Switchenko, Donna Mister, Saul Harari, Shahrzad Ehdaivand, Xiaoxian Li, Mylin Torres and David Yu. CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response After Neoadjuvant Chemotherapy. Int J Breast Cancer. 2018 Oct 14;2018:6945129. doi: 10.1155/2018/6945129. eCollection 2018. PMID: 30405916.

2017

  1. Wright N, Rida P, Krishnamurti U, Xiaoxian Li. Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed). 2017 Jan 1; 22:193-211. 2017 Jan 1;22:193-211. doi: 10.2741/4481. PMID: 27814611.
  2. Xiaoxian Li, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL. Triple negative breast cancer has worse overall survival and cause-specific survival than non-triple negative breast cancer. Breast Cancer Res Treat. 2017 Jan;161(2):279-287. doi: 10.1007/s10549-016-4059-6. Epub 2016 Nov 25. PMID: 27888421.
  3. Krishnamurti U, Wetherilt C, Yang J, Peng L, Xiaoxian Li. Tumor infiltrating lymphocytes are significantly associated with overall survival and disease free survival in triple negative but not estrogen receptor positive breast cancers without neoadjuvant treatments. Hum Pathol. 2017 Jun;64:7-12. doi: 10.1016/j.humpath.2017.01.004. Epub 2017 Jan 30. PMID: 28153508.
  4. Angela Ogden, Chakravarthy Garlapati, Xiaoxian Li, Ravi Turaga, Nikita Wright, Shristi Bhattarai, Karuna Mittal, Ceyda Wetherilt, Uma Krishnamurti, Michelle Reid, Mildred Jones, Meenakshi Gupta, Remus Osan, Sonal Pattni, Ansa Riaz, Sergey Klimov, Arundhati Rao, Guilherme Cantuaria, Padmashree Rida, and Ritu Aneja. Multi-institutional study of nuclear KIFC1 as a biomarker of poor prognosis in African American women with triple-negative breast cancer. Sci Rep. 2017 Feb 20;7:42289. doi: 10.1038/srep42289. PMID: 28218233.
  5. Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il'yasova D, Krishnamurti U, Xiaoxian Li, Reid MD, Gupta M, Rida PC, Osan R, Aneja R. Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLoS One. 2017 Jan 13;12(1):e0170095. doi: 10.1371/journal.pone.0170095. eCollection 2017. PMID: 28085947.
  6. Hou Y, Zynger D, Xiaoxian Li, Li Z. Comparison of Oncotype DX with modified Magee equation recurrent scores in low-grade invasive carcinoma of breast. 2017 Aug 1;148(2):167-172. doi: 10.1093/ajcp/aqx059. PMID: 28898988.
  7. Xiaoxian Li, Jing Yang, Uma Krishnamurti, Lei Huo, Ruth O’Regan, Ritu Aneja, Limin Peng. Hormonal receptor positive breast cancer has worse prognosis in male patients than in female patients. Clin Breast Cancer. 2017 Aug;17(5):356-366. doi: 10.1016/j.clbc.2017.03.005. Epub 2017 Apr 28. PMID: 28576631.
  8. Xiaoxian Li, Wei B, Sonmez C, Li Z, Peng L. High tumor budding count is associated with adverse clinicopathologic features and poor prognosis in breast carcinoma. Hum Pathol. 2017 Aug;66:222-229. doi: 10.1016/j.humpath.2017.06.008. Epub 2017 Jun 24. PMID: 28655638.
  9. Xiaoxian Li, Oprea-Ilies GM, Krishnamurti U. New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. Arch Pathol Lab Med. 2017 Apr;141(4):490-498. doi: 10.5858/arpa.2016-0288-SA. Epub 2017 Feb 28. PMID: 28353377.
  10. Arciero CA, Yang J, Peng L, Ward KC, O’Regan R, Sahin AA and Xiaoxian Li. African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Res Treat. 2017 Dec;166(3):743-755. doi: 10.1007/s10549-017-4484-1. Epub 2017 Aug 30. PMID: 28856481.

2016

  1. Martinez A, Cohen C, Hanley K, Xiaoxian Li. ER and CK5 are reliable markers to separate usual ductal hyperplasia from atypical ductal hyperplasia and low grade ductal carcinoma in situ. Arch Pathol Lab Med. 2016 Jul;140(7):686-689. doi: 10.5858/arpa.2015-0238-OA. Epub 2016 Apr 26. PMID: 27116088.
  2. Davis DG, Siddiqui MT, Oprea-Ilies G, Stevens K, Osunkoya AO, Cohen C, and Xiaoxian Li.GATA-3 and FOXA1 expression are useful to differentiate breast carcinoma from other carcinomas. Hum Pathol. 2016 Jan;47(1):26-31. doi: 10.1016/j.humpath.2015.09.015. Epub 2015 Sep 30. PMID: 26527523.
  3. Xiaoxian Li, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers predicting pathological complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol, 2016 Jun;145(6):871-8. doi: 10.1093/ajcp/aqw045. Epub 2016 Jun 12. PMID: 27298399. Selected for CME credit.
  4. Han CH, Xiaoxian Li, Khanna N. Epithelioid Sarcoma of the Vulva and Its Clinical Implication: A Case Report and Review of the Literature. Gynecol Oncol Rep. 2016 Jan 9;15:31-3. doi: 10.1016/j.gore.2016.01.001. eCollection 2016 Jan. PMID: 26937486.
  5. Funmilayo Tade, Oluwaseun Odewole, Michael Cohen, Toncred Styblo, Xiaoxian Li, Anna Holbrook, Mary S. Newell, Bital Savir-Baruch, Mark M. Goodman, David M. Schuster. Anti-3-[18F] FACBC (Fluciclovine) PET-CT of Breast Cancer: An Exploratory Study. Journal of Nuclear Medicine. 2016 Sep;57(9):1357-63. doi: 10.2967/jnumed.115.171389. Epub 2016 Apr 7. PMID: 27056619.
  6. Jennis M,  Kung P, Basu S, Budina-­‐Kolomets A, Leu J, Khaku S, Scott JP, Cai KQ, Campbell MR, Porter DK, Wang X, Bell DA, Xiaoxian Li, Garlick DS, Liu Q, Hollstein M, George DL, and Murphy ME. An African‐specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Gene and development. 2016 Apr 15;30(8):918-30. doi: 10.1101/gad.275891.115. Epub 2016 Mar 31. PMID: 27034505.
  7. Xiaoxian Li, Ceyda Sonmez Wetherilt, Uma Krishnamurti, Jing Yang, Yamin Ma, Toncred M. Styblo, Jane L. Meisel, Limin Peng, Momin T. Siddiqui, Cynthia Cohen, Ritu Aneja. Stromal PD-L1 expression is associated with better disease free survival in triple negative breast cancer. Am J Clin Pathol, 2016 Oct;146(4):496-502. doi: 10.1093/ajcp/aqw134. PMID: 27686176. Selected for CME credits.
  8. Dave B, Gonzalez DD, Liu ZB, Xiaoxian Li, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC. Role of RPL39 in Metaplastic Breast Cancer. J Natl Cancer Inst. 2016 Dec 31;109(6):djw292. doi: 10.1093/jnci/djw292. Print 2017 Jun. PMID: 28040796.

2015 and before

  1. Vander Heiden MG, Chandel NS, Xiaoxian Li, Schumacker PT, Colombini M, Thompson CB. Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival. Proceedings of National Academy of Sciences. 2000 Apr 25;97(9):4666-4671. doi: 10.1073/pnas.090082297. PMID: 10781072.
  2. Levadny V, Colombini M, Xiaoxian Li, Aguilella VM. Electrostatics explains the shift in VDAC gating with salt activity gradient. Biophysical Journal. 2002 Apr;82(4):1773-1783. doi: 10.1016/S0006-3495(02)75528-8. PMID: 11916837.
  3. Xiaoxian Li, Colombini M. Catalyzed insertion of proteins into phospholipid membranes: specificity of the process. Biophysical Journal. 2002 Nov;83(5):2550-2559. doi: 10.1016/S0006-3495(02)75266-1. PMID: 12414689.
  4. Vander Heiden MG*, Xiaoxian Li*, Gottleib E, Hill RB, Thompson CB, Colombini M. Bcl-xLpromotes the open configuration of VDAC and metabolite passage through the outer mitochondrial membrane. Journal of Biological Chemistry. 2001 Jun 1;276(22):19414-19419. doi: 10.1074/jbc.M101590200. Epub 2001 Mar 20. PMID: 11259441. * Co-first authors
  5. Xiaoxian Li, Davis B, Haridas V, Gutterman GU, Colombini M. Proapoptotic Triterpene electrophiles (avicins) form channels in membranes: cholesterol dependence. Biophysical Journal.  2005 Apr;88(4):2577-2584. doi: 10.1529/biophysj.104.049403. Epub 2005 Jan 14. PMID: 15653745.
  6. Xiaoxian Li, Dumont P, Della Pietra A, Murphy M. The codon 47 polymorphism in p53 is functionally significant. Journal of Biological Chemistry. 2005 Jun 24;280(25):24245-24251. doi: 10.1074/jbc.M414637200. Epub 2005 Apr 25. PMID: 15851479.
  7. Nguyen DM, Sam K, Tsimelzon A, Xiaoxian Li, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O’Connel P, Chang JC. Molecular Heterogeneity of inflammatory breast cancer: A hyperproliferative phenotype. Clinical Cancer Research. 2006 Sep 1;12(17):5047-5054. doi: 10.1158/1078-0432.CCR-05-2248. PMID: 16951220.
  8. Haridas V, Xiaoxian Li, Mizumachi T, Higuchi M, Lemeshko VV, Colombini M, Gutterman JU. Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane. 2007 May;7(3):234-240. doi: 10.1016/j.mito.2006.12.005. Epub 2007 Jan 12. PMID: 17317337.
  9. Xiaoxian Li, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of National Cancer Institute. 2008 May 7;100(9):672-679. doi: 10.1093/jnci/djn123. Epub 2008 Apr 29. PMID: 18445819.
  10. Xiaoxian Li, Parke RB, Rushton JR, Sienko A, Zhai QJ. An unusually large granular cell tumor of the pharynx: a case report and literature review. International Journal of Clinical and Experimental Pathology. 2009;2(3):300-302. Epub 2008 Oct 1. PMID: 19079624.
  11. Creighton CJ*, Xiaoxian Li*, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of National Academy of Sciences. 2009 Aug 18;106(33):13820-13825. doi: 10.1073/pnas.0905718106. Epub 2009 Aug 3. PMID: 19666588.  * Co-first authors
  12. Xiaoxian Li, Deavers M, Guo M, Liu P, Gong, Y, Albarracin, CT, Middleton LP, Huo L. The Effect of Prolonged Cold Ischemia Time on Estrogen Receptor immunohistochemistry in Breast Cancer. Modern Pathology. 2013 Jan;26(1):71-78. doi: 10.1038/modpathol.2012.135. Epub 2012 Aug 17. PMID: 22899286.
  13. Xiaoxian Li, Schwartz MR, Ro JY, Ayala AG, Zhai QJ. Diagnostic Utility of E-cadherin and P120 Catenin Cocktail Immunostain in Distinguishing DCIS from LCIS.  International journal of Clinical and Experimental Pathology. 2014 Apr 15;7(5):2551-2557. eCollection 2014. PMID: 24966968.
  14. Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Xiaoxian Li, Gilcrease M, Lai Z, Chen Y, Huang TH, Shen H, Liu X, Ferrari M, Zhan M, Wong ST, Kumaraswami M, Mittal V, Chen X, Gross SS, Chang JC. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8838-8843. doi: 10.1073/pnas.1320769111. Epub 2014 May 29. PMID: 24876273.
  15. Pannu V, Mittal K, Cantuaria G, Reid MD, Xiaoxian Li, Donthamsetty S, McBride M, Klimov S, Osan R, Gupta MV, Rida PC, Aneja R. Rampant centrosome amplification underlies more aggressive disease course of triple negative breast cancers. Oncotarget. 2015 Apr 30;6(12):10487-10497. doi: 10.18632/oncotarget.3402. PMID: 25868856.
  16. Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Xiaoxian Li, Torres M, O'Regan RM. High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy. Clin Breast Cancer. 2015 Feb;15(1):31-36. doi: 10.1016/j.clbc.2014.06.004. Epub 2014 Jun 24. PMID: 25065563.

Review Articles

  1. Wright N, Rida P, Krishnamurti U, Xiaoxian Li. Aneja R. Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity. Front Biosci (Landmark Ed). 2017 Jan 1; 22:193-211. 2017 Jan 1;22:193-211. doi: 10.2741/4481. PMID: 27814611.
  2. Xiaoxian Li, Krishnamurti U, Oprea-Ilies G. New developments in breast cancer and their impacts on daily practice in pathology. Review. Arch Pathol Lab Med. 2017 Apr;141(4):490-498. doi: 10.5858/arpa.2016-0288-SA. Epub 2017 Feb 28. PMID: 28353377.
  3. Tejaswini P. Reddy; Roberto Rosato; Xiaoxian Li; Stacy Moulder; Helen Piwnica-Worms; Jenny C. Chang. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020 Nov 4;22(1):121. doi: 10.1186/s13058-020-01353-z.PMID: 33148288 
  4.  Xiaoxian Li, Christopher Febres-Aldana, Hong Zhang, Xinmin Zhang, Imran Uraizee, Ping Tang. Updates on lobular neoplasms, papillary, adenomyoepithelial and fibroepithelial lesions of the breast. Arch Pathol Lab Med. 2021 Jul 16. doi: 10.5858/arpa.2021-0091-RA. Online ahead of print. PMID: 34270716
  5. Elizabeth Sakach, Ruth O’Regan, Jane Meisel, Xiaoxian Li. Molecular classification of triple negative breast cancer and the emergence of targeted therapies. Clin Breast Cancer. 2021 Dec;21(6):509-520. doi: 10.1016/j.clbc.2021.09.003. Epub 2021 Sep 17. PMID: 34629314
  6. Di Ai, Keith Sweeney, Xiaoxian Li. Short review of malignant adenomyoepithelioma of the breast. Human Pathology Reports, Volume 27, March 2022. org/10.1016/j.hpr.2021.300583